JAK-2/3-IN-3 (化合物 ST4j) 是一种强效的JAK2/3抑制剂,其对JAK2和JAK3的IC50值分别为 13.00 和 14.86 nM。JAK-2/3-IN-3 以剂量和时间依赖的方式抑制JAK2的自磷酸化并诱导细胞凋亡。JAK-2/3-IN-3 可用于淋巴衍生疾病和白血病的研究。
生物活性 | JAK-2-/3-IN-3 (compound ST4j) is a potentJAK2/3inhibitor withIC50s of 13.00 and 14.86 nM forJAK2andJAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation ofJAK2and inducesapoptosisin a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia[1]. |
IC50& Target[1] | JAK2 13.00 nM (IC50) | JAK3 14.86 nM (IC50) |
|
体外研究 (In Vitro) | JAK-2/3-IN-3 (0-100 μM; 72 h) specifically inhibits human erythroleukemia cells with low toxicity to the normal cells[1]. JAK-2/3-IN-3 inhibits human erythroleukemia TF1 cell growth via the JAK2/STAT5 signaling pathway[1]. JAK-2/3-IN-3 (15.53 μM; 24, 48, 72 h) induces cytotoxicity via apoptosis in a time-dependent manner in TF1 cells[1]. JAK-2/3-IN-3 (IC25, IC50, IC75; 24 h) induces cytotoxicity via apoptosis in a dose-dependent manner in TF1 cells[1].
Apoptosis Analysis[1] Cell Line: | TF1 cells | Concentration: | 15.53 μM | Incubation Time: | 24, 48, 72 h | Result: | Increased cells apoptotic by ~20%, ~40% and ~70%, after 24-, 48- and 72-h incubations, respectively. Increased cells apoptotic by ~15%, 20%, and 30% with concentration of IC25, IC50and IC75, respectively. |
Cell Cytotoxicity Assay[1] Cell Line: | TF1, HEL, Vero and HepG2 cells | Concentration: | 0-100 μM | Incubation Time: | 72 h | Result: | Inhibited growth of TF1 and HEL cells, with IC50s of 15.53 and 17.90 μM. Showed low toxic to normal Vero cells and HepG2 cells (IC50of >100 μM in Vero cells and of >50 μM in HepG2 cells). |
|
分子量 | |
Formula | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |